Accelerated First in Human Trial of a Promising SARS-CoV-2 Antiviral

The critical need for potent SARS-CoV-2 treatments has required acceleration of development timelines without compromising safety. Learn how one biotech company was able to administer the first human dose of a new antiviral just 23 days after first meeting with the CRO. Within nine weeks this promising new product was ready for Phase II testing, instead of the standard eight months for a similar study.